The Rationale for Inhibiting 5α-Reductase Isoenzymes in the Prevention and Treatment of Prostate Cancer

    February 2008 in “ ˜The œJournal of urology/˜The œjournal of urology ”
    Donald J. Tindall, Roger S. Rittmaster
    Studysummary This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on europepmc.org →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Discovery and Clinical Development of Dutasteride, a Potent Dual 5α-Reductase Inhibitor Current topics in medicinal chemistry · 2006
    2. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor ˜The œJournal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism · 2004